When will serputinib/serpatinib be available?

It is understood that although Selpercatinib/Selpercatinib is still under investigation in the clinical trial NCT04211337, it was obtained on May 8, 2020 Accelerated approval from the U.S. Food and Drug Administration (FDA) for specific RET-driven cancer indications, such as non-small cell lung cancer and thyroid cancer. Loxo Oncology Inc is currently marketed under the brand name RETEVMO. Septinib has also been approved by the European Commission and is sold under the trade name Retsevmo. Seputinib has also been approved by the National Medical Products Administration for domestic marketing and is sold under the trade name Ruituo.

Seputinib was found to be effective in treating cancers involving changes in the RET gene, reducing cancer size in most patients. Its side effects are considered manageable. The most common side effects include increased liver enzymes, increased blood sugar, decreased white blood cell and platelet counts, decreased protein levels, decreased calcium levels, increased total cholesterol, increased creatinine and decreased sodium levels, dry mouth, diarrhea, high blood pressure, fatigue, edema, rash, and constipation.

SeputinibThe original drug has not been included in medical insurance since it was launched in China. The common specifications80mg*56 capsules may cost more than 10,000 yuan per box. There are European and American versions of the original drugs sold overseas, with the price of each box ranging from 20,000 to more than 100,000 yuan (prices may fluctuate due to exchange rates). Generic drugs of Seputinib have also been put on the market for sale overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 40mg*120 capsules produced by a Laos pharmaceutical factory is more than RMB 4,000 per box (the price may fluctuate due to exchange rates).